Addex Therapeutics (ADXN) Research & Development (2019 - 2026)
Addex Therapeutics (ADXN) posted Research & Development of -$46136.9 for Q1 2026, down 102.86% sequentially from $1.6 million in Q4 2025, and up 73.42% YoY from -$26604.0 in Q1 2025.
Addex Therapeutics (ADXN) Research & Development (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Research & Development for 8 years, with the latest figure at -$46136.9 in Q1 2026.
- Quarterly Research & Development rose 73.42% year-over-year to -$46136.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $999866.8 (down 8.35% YoY) and the FY2025 annual result came in at $810097.4, down 16.58% from the prior year.
- Research & Development retreated to -$46136.9 in Q1 2026 per ADXN's latest filing, from $1.6 million in the prior quarter.
- Over five years, Research & Development peaked at $21.3 million in Q4 2022 and troughed at -$6.0 million in Q2 2022.
- A 5-year average of $679767.5 and a median of -$280835.4 in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 94.57% in 2023, down 88.23% in 2023.
- Over 5 years, Research & Development stood at $21.3 million in 2022, then slumped by 88.23% to $2.5 million in 2023, then slipped by 25.19% to $1.9 million in 2024, then retreated by 13.92% to $1.6 million in 2025, then sank by 102.86% to -$46136.9 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$46136.9, $1.6 million, and -$285427.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -46,136.90 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46,136.90 |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | -285,427.50 |
| Jun 30, 2025 | -283,194.70 |
| Mar 31, 2025 | -173,584.49 |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | -236,051.54 |
| Jun 30, 2024 | -375,214.53 |
| Mar 31, 2024 | -280,835.38 |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | -555,532.54 |
| Jun 30, 2023 | -324,281.47 |
| Mar 31, 2023 | -276,094.33 |
| Dec 31, 2022 | 21.30 Mn |
| Sep 30, 2022 | -2.86 Mn |
| Jun 30, 2022 | -5.97 Mn |
| Mar 31, 2022 | -4.08 Mn |
| Dec 31, 2021 | 24.06 Mn |
| Sep 30, 2021 | -3.12 Mn |
| Jun 30, 2021 | -4.09 Mn |